Zenas BioPharma, Inc.
NASDAQ:ZBIOBiotechnology
+$0.64 today
- Market cap
- $1.79B
- Beta
- -0.69
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$7.64
Volume 0.48M
Average 0.71M
ZBIO Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Zenas BioPharma, Inc.NASDAQ: ZBIO
Short-term Investments · Q1 FY2026 · quarter ended Mar 2026
Short-term investments rises 87.3% from a year ago
Short-term investments stood at $216.98M at the end of Q1 FY2026, up 87.3% from a year earlier and down 6.7% from the prior quarter.
Context
- Short-term investments amounted to 29.0% of total assets at the end of Q1 FY2026, down 5.7 pp from a year earlier.
- Short-term investments increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether short-term investments keeps rising in the next quarterly balance sheet after a +87.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 232.55M USD
- Year-over-year change
- +649.6%
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 232.55M | +649.6% |
| FY2024 | 2024-12-31 | 31.02M | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Short-term Investments vs competitors
How ZBIO compares with its peers on the latest reported figures
- ZBIO's Mar 2026 short-term investments of $216.98M is the highest of the 8 companies compared; the peer median is $37.99M.
- Its year-over-year change of +87.3% is the highest of 4, against a peer median of -45.1%.
- Short-term investments amounts to 29.0% of total assets for ZBIO, versus a peer median of 13.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $216.98M | +87.3% | — | 29.0% | |
UPBUpstream Bio, Inc. | Mar 2026 | $197.86M | -45.1% | — | 62.2% |
| Mar 2026 | $76.76M | +2.4% | -25.7% | 38.6% | |
| Mar 2026 | $49.82M | -70.1% | -9.4% | 18.9% | |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $37.99M | — | — | 13.1% |
| Sep 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Dec 2025 | $0 | — | — | 0.0% | |
| Peer median (excluding ZBIO) | $37.99M | -45.1% | -17.5% | 13.1% | |
Competitors are the stored peer set for ZBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Zenas BioPharma, Inc.
NASDAQ:ZBIO
Intrinsic Alpha fair value
Locked
Current Price
$26.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.